(Total Views: 511)
Posted On: 07/01/2022 11:36:33 AM
Post# of 148899
I'm not ok with the increased # of authorized shares. We just voted end of last year to allow for the 200million shares. We were told they would be used sparingly. to start talking about the need for more for the same reason that was given last year is basically admitting they did not use the last 200 million shares sparingly and/or they catalyst that was to be born out of the flexibility having those shares did not happen.
We don't have any trials going on, we don't have the expenses we once had. Management needs to deliver on what the last share float increase was suppose to do. I don't care if the whole team and the BOD work for free, they owe us.
I don't understand how re-formatting the Amarex data takes this long, I don't understand why the Brazil trials were clinical holds last CC and now they are just pauses from DSMC? Also, the big one, Is why the clincal hold has not been resolve in the HIV BLA. It is just un-acceptable that this is holding everything up and they did not clearly state that they have everything together and just need the FDA to lift the Clinical hold. The management team must resolve this and I have zero interest in excuses about past management.
As for Dr Recknor's excitement about the data from the Nash trial, I was left wondering how we are just now figuring out how this drug works? It would seem that the FDA just does not look at the results of a trial, they want reasons why it worked and why different doses do different things. At this point we have done many trials and I get the feeling the FDA is frustrated asking the same questions. We have to know everything about our own product, to be still learning after 8+ years just says we did not really design the right trials and do the correct research to get FDA approval.
We paid for this, time to get our moneys worth.
We don't have any trials going on, we don't have the expenses we once had. Management needs to deliver on what the last share float increase was suppose to do. I don't care if the whole team and the BOD work for free, they owe us.
I don't understand how re-formatting the Amarex data takes this long, I don't understand why the Brazil trials were clinical holds last CC and now they are just pauses from DSMC? Also, the big one, Is why the clincal hold has not been resolve in the HIV BLA. It is just un-acceptable that this is holding everything up and they did not clearly state that they have everything together and just need the FDA to lift the Clinical hold. The management team must resolve this and I have zero interest in excuses about past management.
As for Dr Recknor's excitement about the data from the Nash trial, I was left wondering how we are just now figuring out how this drug works? It would seem that the FDA just does not look at the results of a trial, they want reasons why it worked and why different doses do different things. At this point we have done many trials and I get the feeling the FDA is frustrated asking the same questions. We have to know everything about our own product, to be still learning after 8+ years just says we did not really design the right trials and do the correct research to get FDA approval.
We paid for this, time to get our moneys worth.
(8)
(2)Scroll down for more posts ▼
